Introduction
The importance of the pituitary in the control of growth was firmly established between 1900 and 1920 (Evans 1923-24) , and the existence of growth hormone (GH) as the major pituitary factor stimulating growth was established in the 1940s with the purification of bovine GH (Li et al. 1945) . GH is a polypeptide of molecular weight 22 000 and contributes 4-10% of the wet weight of the pituitary. Its primary clinical interest is that GH deficiency induces dwarfism, while GH excess causes gigantism in children and acromegaly in adults. There is also circumstantial evidence that GH may play a role in the production of the microvascular complications of diabetes mellitus, although the mechanism is uncertain.
The secretion of GH is episodic in normal subjects and its regulation is complex. Our understanding of the factors influencing secretion, and in particular of the role of the hypothalamic regulatory peptides, has increased greatly in recent years and this review will concentrate on these more recent developments. Major differences exist in the regulation of GH secretion in humans and animals: discussion here will be concerned primarily with GH secretion in humans, and will examine the abnormalities of GH secretion which occur in disease states where GH is thought to play a role in the pathogenesis of the clinical syndrome. These include acromegaly, pituitary dwarfism and diabetes mellitus.
Constitutional factors
Circulating GH levels, both in the basal state and after provocative stimuli, are higher in females than in males (Frantz & Rabkin 1965) . This difference is probably oestrogen-induced in that GH concentrations rise in men given exogenous oestrogen therapy. Circulating GH levels are higher in adolescence than in prepubertal children and young adults (Plotnick et al. 1975) . Obesity is associated with decreased circulating GH levels compared with normal weight controls (Copinschi et al. 1967 ).
Stress and physiological factors GH levels are elevated after major trauma or elective surgery or other forms of stress, although the rise is less consistent than that observed for other stress hormones. Thus, for example, elevated GH concentrations are present in only 50% of patients presenting with diabetic ketoacidosis (Cryer & Daughaday 1970) . Prolonged starvation is associated with increased levels and strenuous exercise is a consistent stimulus, although with mild exertion GH secretion may remain unaltered (Hansen 1973) . Between 50% and 75% of the total GH secreted over a 24-hour period occurs at night within 90 minutes of the onset of sleep, and smaller secretory bursts occur thereafter.
Metabolic substrates An increase in blood glucose suppresses GH secretion and this effect is observed within the physiological blood glucose range (Beck et al. 1966) . Similarly an increase in circulating concentrations of certain other metabolic fuels, such as non-esterified fatty acids and the ketone bodies, inhibits GH release although the physiological role of these substrates in GH regulation is uncertain. A decrease in blood glucose to hypoglycaemic levels stimulates GH release. 'Accepted 15 November 1984 i. 1985 The Royal Society of Medicine
In the normal person a fall in blood glucose within the physiological range and without production of hypoglycaemia also elicits GH secretion (Santiago et al. 1980) . Certain amino acids, particularly arginine and leucine, are potent GH stimulants after intravenous injection to pharmacological concentrations (Cremer et al. 1968) . High protein, low carbohydrate meals also induce GH release.
Central nervous system (CNS) neuromediators Much of our information on the role of CNS neuromediators in the regulation of GH secretion comes from indirect experiments in which the neuromediator or its agonist or antagonist were administered systematically or into the cerebrospinal fluid and the effects on GH secretion were observed. In physiology the neuromediators have a primary action locally in the hypothalamus or elsewhere and the effects may be very different when they act in this way.
With these limitations, present evidence suggests that a-adrenergic stimulation increases GH secretion while fl-adrenergic effects are inhibitory (Martin 1973) . Dopamine has a dual action, stimulating GH release in the basal state, while inhibiting GH secretion induced by stimuli such as hypoglycaemia or arginine (Bansal et al. 1981) . Stimulatory effects of other neuromediators such as serotonin, vasopressin and the opioid peptides have also been observed (Daughaday 1981) . Several gut hormones, which are present in the central nervous system, stimulate the release of GH but their physiological significance is unknown; these include VIP, substance P, neurotensin and bombesin.
Releasing and inhibitory factors at the pituitary Secretion of GH from the pituitary somatotroph is controlled by at least one inhibitory and one stimulatory factor released from the hypothalamus into the hypothalamic-hypophyseal portal venous system. The GH release inhibitory factor, somatostatin, a 14 amino acid peptide, was isolated from hypothalami by the group of Guillemin in 1973 (Brazeau et al. 1973) . The amino acid sequence of somatostatin is common to most animal species studied. Somatostatin immunoreactivity is concentrated in the median eminence and in the ventromedial, arcuate, supraoptic and periventricular nuclei of the hypothalamus (Pelletier 1979) . The peptide is a potent inhibitor of GH release from pituitary cells in vitro. Somatostatin has a widespread distribution elsewhere in the CNS in addition to the pancreas and gut, and has numerous other actions such as modification of gastrointestinal absorption and inhibition of secretion of hormones such as insulin, glucagon and numerous gut hormones (Reichlin 1983) . In the present context, concentrations of somatostatin sufficient to inhibit GH release have been demonstrated in the hypothalamic-hypophyseal portal venous blood of animals (Chihara et al. 1981) . Further evidence for a physiological role for somatostatin in vivo comes from animal experiments in which administration of antibodies to somatostatin induce an elevation in circulating GH concentrations (Tannenbaum et al. 1978) .
Hypothalamic extracts also contain GH stimulatory activity. Detailed knowledge of the nature of hypothalamic GH-releasing factor (GRF) came from indirect data in which GH stimulatory substances were secreted ectopically by human pancreatic tumours. Patients with these tumours had developed classical acromegaly and pituitary histology revealed somatotroph hyperplasia. Chemical extraction of the tumours after surgery revealed that the GH stimulatory activity resided in a peptide moiety -in one tumour in a single 40 amino acid peptide (Rivier et al. 1982) , and in a further tumour three peptides were produced, the 40 amino acid form and two additional forms of 44 and 37 amino acids . These peptides are designated hpGRF44, hpGRF40 and hpGRF37. All three peptides have biological activity. Chemical identity of the 44 amino acid pancreatic GRF with the true human hypothalamic GRF has recently been demonstrated. Species variation exists in that the rat hypothalamic GRF differs, although there is considerable amino acid homology with hpGRF44 . GRF immunoreactivity has been observed in the arcuate nucleus, with fibres projecting to the median eminence in the primate hypothalamus (Bloch et al. 1983 ). It has not yet been demonstrated in the hypothalamic-hypophyseal blood, but GRF potently releases GH from pituitary cells in vitro. Unlike somatostatin which has diverse endocrine effects, GRF exhibits considerable specificity for GH, although a minor stimulatory effect on prolactin release has been inconsistently observed at high dosage. Evidence for a physiological role of GRF in animals comes from experiments in which administration of antisera to GRF inhibits the spontaneous secretory bursts of GH secretion (Miki et al. 1984 .
Chemical synthesis of somatostatin and the GRFs has enabled studies of their actions to be performed in humans. Somatostatin suppresses basal GH release and inhibits GH secretion when stimulated by a variety of secretagogues including arginine and insulin hypoglycaemia (Guillemin & Gerich 1976) . It has a short half-life (1-3 minutes) and has therefore been administered by continuous intravenous infusion, on cessation of which a rebound rise in GH secretion may be observed. Infusion rates of 1 gg/min are sufficient totally to suppress basal GH release. GRF is more slowly cleared after intravenous injection (half-life 52 minutes for the 40 amino acid peptide) and the GH response after bolus injection is apparent within 5 minutes (Frohman et al. 1984 , Thorner et al. 1983 . Maximum responses are observed at 1.0 jg/kg body weight and responses are highly variable between normal subjects. At doses of hpGRF40 greater than 2.0 ,g/kg body weight, a prolonged and biphasic pattern of GH release is observed. With continuous infusion of hpGRF44 (0.3 ,g/kg/h for 4 hours) a multiphasic GH response occurs with a first peak at 15-90 minutes and a second peak at 105-195 minutes (Davies et al. 1984b) (Figure 1 ). As with bolus injections, there is considerable inter-individual variation in response. With prolonged continuous infusion or repeated intravenous boluses, a decrease in mean GH response is observed, suggesting either depletion of readily releasable GH or decreased pituitary somatotroph sensitivity to GRF due, for example, to downregulation of GRF receptors. GH responses to GRF are impaired in the obese and the elderly but the mechanism is unknown.
Somatostatin inhibits GRF-stimulated GH release from pituitary cells in vitro and after GRF administration in vivo in man. The antagonistic effects in vivo are dose-related (Figure 1 ). (10,ug) was administered as an intravenous bolus to a normal subject at 60min, on 2 occasions. On the first, oral glucose (75 g) was taken at 0 minutes (A), and on the second, hpGRF44 was given without glucose (B). On a third occasion, oral glucose (75 g) was taken at 0 minutes without administration of hpGRF44 (c). Blood samples for GH measurement were taken from an indwelling intravenous cannula inserted under local anaesthesia at -60 minutes and all studies were performed while the subject was recumbent after an overnight fast The concept has thus arisen of the regulation of GH secretion by the relative quantities of somatostatin and GRF released from the hypothalamus into the hypothalamic-hypophyseal portal venous system. It is probable that most of the factors known to influence the secretion of GH do so by changing the absolute or relative amounts of somatostatin or GRF released from the hypothalamus. Glucose-induced suppression of GH release may be mediated by an increase in hypothalamic somatostatin release. Although other interpretations are possible, this is suggested by the ability of oral glucose to suppress the GH response to hpGRF44 in normal man, when compared with the response obtained without glucose (Davies et al. 1 984a) (Figure 2 ). The administration of antisera to GRF abolishes the a-adrenergic and opioid peptide-induced stimulation of GH release in animals, suggesting that these mediators exert their stimulatory effect via release of GRF (Miki et al. 1984) . Much physiology remains to be clarified, however, in particular to ascertain the influence of stimulatory and inhibitory peptides on release of the opposing substance. Preliminary evidence suggests that GRF itself stimulates somatostatin release from hypothalamic cells in culture, although the importance of this in normal physiology remains unknown (Arimura et al. 1984) .
In addition, other agents may act at the pituitary to stimulate or inhibit GH release. Other peptides may have a physiological role, and non-peptide substances such as dopamine exert effects on GH release from pituitary cells in vitro. Thus while increased hypothalamic dopamine in animals stimulates GH secretion, possibly through increased GRF release, the direct effect of dopamine at the pituitary is to inhibit GH secretion. As dopamine is present in high concentration in hypothalamic-hypophyseal portal venous blood, the effects in vivo will depend on the balance between the stimulatory hypothalamic and inhibitory pituitary actions.
Feedback inhibition of GH release: short-loop and long-loop feedback GH in animals exerts negative feedback inhibition on further GH release. This effect is probably mediated through increased hypothalamic somatostatin release, although a direct inhibitory effect on the pituitary somatotroph may coexist (Tannenbaum 1980) . There is also evidence that GH-dependent peptides, the somatomedins, which mediate many of the actions of GH, exert negative feedback inhibition on GH release. Prior GH administration diminishes the GH response to intravenous GRF in man, suggesting that similar feedback mechanisms are present .
GH secretion in disease Acromegaly Acromegaly is most commonly caused by a pituitary adenoma secreting excessive quantities of GH. The relative increase in GH secretion is highly variable in individual patients, with mean GH levels ranging from just outside the normal range to increases of several hundred-fold. There is a loose positive correlation between tumour size and circulating GH levels, and younger patients tend to have both larger tumours and higher GH concentrations than are observed in older age groups.
The characteristic and diagnostic abnormality of GH regulation is the failure of suppression after oral glucose. Certain patients demonstrate a paradoxical rise. Numerous other abnormalities exist, including the stimulation of GH release after intravenous thyrotrophinreleasing hormone (TRH) which is not observed in normal subjects, and the suppression of GH secretion by dopamine agonists as opposed to the stimulation observed in normals (Gomez-Pan et al. 1975) . The GH rise with TRH and fall with dopamine agonists are linked in that they tend to occur in the same patients.
The GH response to GRF is variable in acromegaly. Preliminary information suggests that the response to hpGRF40 is normal in those patients who show some suppression of GH secretion with oral glucose. Those patients who demonstrate a paradoxical rise in GH with oral glucose exhibit exaggerated GH responses to hpGRF40 (Wood et al. 1983) .
There is no ready explanation for the abnormal GH regulation in acromegaly. A primary hypothalamic disturbance causing increased release of GRF has been claimed to lead to adenomatous transformation of the chronically-hyperstimulated somatotrophs (Melmed et al. 1983) . Certainly, patients with true somatotroph hyperplasia secondary to ectopic production of GRF exhibit the same abnormalities of GH secretion as are observed in acromegalics with pituitary adenomas, notably the abnormal responses to glucose, TRH and dopamine agonists . The occasional coexistence of acromegaly, pituitary adenomas and hypothalamic structural abnormalities, such as chordomas or ganglioneurocytomas, also suggests a hypothalamic disorder leading to pituitary adenomatous change. In favour of a primary pituitary disorder in the aetiology of acromegaly is the observation that somatotroph hyperplasia is absent in the pituitary tissue adjacent to the adenoma. A major and persisting hypothalamic abnormality of GH regulation is also unlikely after successful surgical adenomectomy, when the GH responses to provocative stimuli become at least qualitatively normal. Finally, circulating GRF concentrations in peripheral blood, measured by both bioassay and radioimmunoassay, are normal in the majority of acromegalics, although it must be emphasized that the relationship between GRF levels in the peripheral circulation and GRF release from the hypothalamus is at present unknown (Penny et al. 1984) .
The case for a hypothalamic versus pituitary aetiology of acromegaly is thus unproven. Care must be exerted not to over-extrapolate from the abnormal GH responses to provocative stimuli. Inappropriate responses of other pituitary hormones to a variety of releasing agents are increasingly recognized in other forms of pituitary tumour and are thus not specific to acromegaly.
GH deficiency
Isolated GH deficiency and GH deficiency associated with one or several other anterior Results originally expressed in ug/l were converted to mU/l assuming 1 mU/l = 2 pg/l pituitary hormone deficiencies are rare disorders characterized by short stature and growth failure in childhood and adolescence. GH deficiency is confirmed by the demonstration of an absent or impaired response to insulin hypoglycaemia or some other provocative test of GH secretion. Deficiency of GH in these patients may be due either to a primary pituitary abnormality of GH synthesis or release, or alternatively the underlying disorder may be hypothalamic with deficient synthesis, release or activity of GRF. Post-mortem studies of the pituitary in idiopathic GH deficiency have demonstrated somatotrophs and immunoreactive GH, suggesting that GH synthesis is preserved (Rimoin & Schechter 1973) .
A series of studies using different regimens with various GRFs has now demonstrated that 25-89% of patients with idiopathic GH deficiency respond to the releasing factors (Table 1) , whether or not other pituitary deficiencies coexist. In those patients with a positive response this response is impaired, however, particularly if the patients have severe GH deficiency by conventional criteria. The pattern of response to continuous intravenous infusion is abnormal in GH deficiency (Figure 3 ) in that multiphasic GH release is usually absent (Davies et al. 1984b) . These data suggest that the primary abnormality is hypothalamic deficiency of GRF in many patients, although the precise interrelationship between GRF and GH synthesis and release has not yet been fully explored. Preliminary evidence suggests that certain patients who do not initially respond to GRF, may do so after intermittent pulsatile GRF administration (0.33 tg/kg hpGRF40 intravenously 3-hourly for 5 days) (Borges et al. 1984) . Furthermore, patients who show no GH response or only a minimal response to a single injection of GRF may demonstrate a measurable rise in somatomedin levels at 24 hours. Long-term trials are necessary to establish the potential usefulness of GRF as therapy for GH deficiency. The ease of manufacture may be greatly assisted and the cost decreased by the development of shorter-chain analogues, such as the 1-29 variety already in existence.
Patients with GH deficiency secondary to pituitary tumours do not, in general, exhibit a hpGRF44, 0.3 ,ug/kg/h, was infused continuously from 0 to 240 minutes in a patient with idiopathic growth hormone deficiency. Note that the GH scale is ten-fold less than that for normal subjects in Figure 1 . Blood samples for GH measurement were taken from an indwelling intravenous cannula inserted under local anaesthesia at -60 minutes, with the patient recumbent after an overnight fast GH response to GRF. Patients with hypothalamic disease caused by tumours or irradiation may or may not respond to GRF, probably reflecting the absence or presence of associated pituitary damage respectively.
Diabetes mellitus
Circulating GH levels are raised in Type I diabetics, particularly in younger subjects and in those with poor diabetic control. Basal levels are increased, as are the 24-hour mean concentrations and the GH responses to exercise and a variety of provocative stimuli (Hansen 1971 ). With extremely careful control of the diabetes to produce near-normoglycaemia, GH levels decline over 1-2 weeks to values similar to those observed in non-diabetics. Circulating GH levels are raised also in non-obese Type II diabetics.
The coexistence of hyperglycaemia, which should suppress the release of GH, and elevated GH levels suggests an abnormality of GH regulation in diabetes mellitus. Raised ketone body and non-esterified fatty acid levels, if present, should also suppress the release of GH. The elevated GH levels are not related to the rapid and large fluctuations in blood glucose which occur in certain patients. In addition, while there is some evidence that insulin itself may stimulate GH release independent of changes in blood glucose, peripheral hyperinsulinaemia cannot explain the elevations in GH concentrations in all patients. Hypersensitivity to GRF has been sought, but the GH response to GRF (both hpGRF40 and hpGRF44) is similar in controls and diabetics (Sharp et al. 1984) . Responses are unaffected, however, by the blood glucose level, being similar at 6 and 13 mmol/l, in marked contrast to the non-diabetic state in which an elevation in blood glucose even within the physiological range suppresses GRF-induced GH release. In normal subjects, the suppressive effect of glucose is thought to be mediated at hypothalamic level, and its absence in diabetics may indicate an impairment of hypothalamic function, most likely a defect in somatostatin release or effect.
It is uncertain if this defect reflects an anatomical change in the diabetic hypothalamus or alternatively results from the abnormal physiological state in diabetes mellitus. Measurements of somatomedin levels have reported low, normal or elevated values in diabetes and these have been both related and unrelated to preceding diabetic control (Merimee et al. 1984) . In view of the feedback inhibition of somatomedins on GH release, variations in GH levels and responsiveness may reflect at least in part the production of these growth factors.
The clinical importance of GH in diabetes resides in its anti-insulin effect and in its possible relationship to microvascular complications. GH is an integral component of the stress response and may contribute to metabolic decompensation in diabetics with intercurrent illness. The nocturnal spikes in GH secretion are the major cause of the 'dawn phenomenon' which describes the increase in insulin requirements observed in Type I patients in the early morning hours. More important, however, is the role of GH in diabetic complications. Complications do not occur in GH-deficient diabetic dwarfs, and hypophysectomy in the past frequently induced marked clinical remission in diabetics with severe retinopathy. Under certain circumstances, patients with retinopathy have higher GH levels than those without, and somatomedin concentrations measured by either bioassay or radioimmunoassay (IGF-1) are higher in the retinopaths (Ashton et al. 1983 , Merimee et al. 1984 . The mechanism by which GH operates is unknown, but the combination of GH excess and insulin deficiency is necessary as retinopathy is extremely uncommon in acromegalics without overt diabetes mellitus.
Conclusions GH regulation is determined by the absolute or relative amounts of somatostatin and GRF released from the hypothalamus into the hypothalamic-hypophyseal portal venous system to act on pituitary somatotrophs. The known influences on GH secretion such as the circadian variation and spontaneous secretory bursts, and the GH responses to adrenergic influences and glucose, may be mediated in this way. Detailed information on the interrelationships between somatostatin and GRF is not yet available and the possibility of as yet unknown stimulatory and inhibitory substances remains. The effects of the known regulatory peptides on pituitary somatotroph sensitivity require evaluation. The effects of somatostatin appear to be persistent over prolonged periods while there is evidence for a declining sensitivity of somatotrophs on prolonged exposure to GRF.
The possibility of treatment of disease states with regulatory peptides, or analogues of these peptides, is exciting. Analogues of somatostatin have been produced, such as an 8 amino acid variant, which have a prolonged action particularly with respect to GH secretion. The potential of these substances in the treatment of acromegaly and endocrine gut tumours is currently being explored, and the possibility of modifying GH secretion in diabetes mellitus holds promise for the treatment or prevention of microvascular complications. The use of GRF in the treatment of GH deficiency is also under evaluation. We can expect the development of other stimulatory and blocking analogues of both somatostatin and GRF which will increase further our understanding of normal physiology, and hopefully they will prove to have a therapeutic role.
